Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).

Men with circulating tumor cell (CTC) AR-V7 positive mCRPC have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive-biomarkers are needed.